Dr. Soff discusses results from a phase II study of romiplostim in treating patients with chemotherapy-induced thrombocytopenia. The agent led to high rates of platelet count correction and reduction in transfusion needs.
Recent Articles
FDA Lifts Clinical Hold on Rusfertide Trials
The U.S. Food and Drug Administration has lifted its full clinical hold on Protagonist Therapeutics’ clinical studies of rusfertide. The clinical hold was announced...
How Can FDA Regulation Build Transparency into Health Care AI Tools?
In October, the U.S. Food and Drug Administration (FDA) held a workshop on the regulation of artificial intelligence (AI) in health care.
While the FDA...
White House Will Invest $100M to Address the Health Care Worker Shortage
The Biden administration has announced it will invest $100 million of funds from the American Rescue Plan to help address the health care worker...
Ruxolitinib Approved for Chronic Graft-Versus-Host Disease
The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older whose disease...
Crizanlizumab Approved for Sickle Cell Disease in the U.K.
Crizanlizumab will become the first new therapy in 20 years to be made available through the U.K.’s National Health Service (NHS) for the treatment...
Current Issue
October 2021, Volume 7, Issue 12
This issue tells the long story of drug shortages, demystifies transfusion services, and more.